17,261 trials
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Fasting Plasma Glucose at Day 1 — 0.20; 0.39; -0.96; -0.47 mmol/L — p=0.2790
Lymphoma
Primary: Phase I Maximum Tolerated Dose (MTD) of Vorinostat — 300 mg/day
Asthma
Primary: Trough Forced Expiratory Volume in One Second (FEV1) After 12 Weeks (Day 85) — 2.190; 2.216; 2.110 Liters
Central Nervous System Tumor, Pediatric · Leukemia · Lymphoma
Primary: Therapy Completion Rate — .25 proportion of patients
Diabetic Macular Edema
Primary: Change in BCVA From Baseline to Week 24 - Last Observation Carried Forward (LOCF) — 2.5; 8.6; 11.4; 8.5 letters correctly read
Streptococcal Infection · Gram-positive Bacterial Infection · Bacterial Infection
Primary: Geometric Mean Concentrations (GMCs) of Antibodies in Mothers and Infants at Delivery/Birth — 5.39; 0.41; 4.37; 0.4 µg/mL
Seizures
Primary: Pharmacokinetic Profile — 0.51 ml/min/kg
Smoking Cessation
Primary: Percentage of Change in Expired Air Carbon Monoxide (CO) at End of Week 2 — -0.52 percentage change
Diabetes Mellitus · Metabolic Syndrome X · Hypercholesterolemia
Primary: Change in Plasma Thiobarbituric Acid Reactive Substance (TBARS) Levels — 2.1; 2.5 nmol/mL
Diabetes Mellitus, Type 1
Primary: Postprandial Glucose Excursion — 17.23; 14.47 milligrams per deciliter (mg/dL) — p=0.3217
Breast Cancer · Stage I Breast Cancer · Stage II Breast Cancer
Primary: Number of Participants With Adverse Events — 17 participants
Continuous Methamphetamine Abuse
Primary: Self-report Effects of High. — 0; 0; 0; 0 units on a scale
Myelodysplastic Syndromes
Primary: Rate of Complete Remission (CR) and Partial Remission (PR) — 5; 1 participants
Rectal Carcinoma
Primary: Rate of Tumor Downstaging Compared With Historical Controls. — 64.4; 64.5 percentage of participants
Leukemia · B-cell Leukemia · Chronic Leukemia
Primary: Number of Subjects Maintaining Partial Response (PR) or Complete Response (CR) — 17 participants